|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CISD3 |
Gene summary for CISD3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CISD3 | Gene ID | 284106 |
| Gene name | CDGSH iron sulfur domain 3 | |
| Gene Alias | MiNT | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0006807 | UniProtAcc | P0C7P0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 284106 | CISD3 | Pat12-B | Human | Stomach | GC | 2.44e-21 | 2.88e-01 | 0.0325 |
| 284106 | CISD3 | Pat13-B | Human | Stomach | GC | 5.04e-11 | 2.71e-01 | 0.0555 |
| 284106 | CISD3 | Pat15-B | Human | Stomach | GC | 8.80e-17 | 3.08e-01 | -0.0778 |
| 284106 | CISD3 | Pat16-B | Human | Stomach | GC | 1.08e-11 | 2.28e-01 | 0.1918 |
| 284106 | CISD3 | Pat17-B | Human | Stomach | GC | 6.20e-11 | 3.07e-01 | 0.3109 |
| 284106 | CISD3 | Pat18-B | Human | Stomach | GC | 6.75e-19 | 2.65e-01 | -0.0432 |
| 284106 | CISD3 | Pat19-B | Human | Stomach | GC | 4.01e-14 | 2.33e-01 | 0.0826 |
| 284106 | CISD3 | Pat22-B | Human | Stomach | GC | 1.03e-45 | 4.34e-01 | -0.1042 |
| 284106 | CISD3 | Pat24-B | Human | Stomach | GC | 3.93e-15 | 3.45e-01 | -0.1184 |
| 284106 | CISD3 | Pat25-A | Human | Stomach | CAG with IM | 1.05e-44 | 4.09e-01 | -0.1648 |
| 284106 | CISD3 | Pat26-A | Human | Stomach | CSG | 2.21e-48 | 4.84e-01 | -0.2402 |
| 284106 | CISD3 | Pat28-A | Human | Stomach | CSG | 1.35e-16 | 3.95e-01 | -0.2594 |
| 284106 | CISD3 | Pat29-A | Human | Stomach | CAG with IM | 3.42e-19 | 6.25e-01 | -0.2769 |
| 284106 | CISD3 | CAG_3 | Human | Stomach | CAG | 6.87e-10 | 3.25e-01 | -0.2766 |
| 284106 | CISD3 | WIM_1 | Human | Stomach | WIM | 4.99e-05 | 3.86e-01 | 0.0335 |
| 284106 | CISD3 | WIM_2 | Human | Stomach | WIM | 6.59e-05 | 4.20e-01 | 0.1159 |
| 284106 | CISD3 | SIM_1 | Human | Stomach | SIM | 2.08e-04 | 3.09e-01 | 0.3573 |
| 284106 | CISD3 | SIM_2 | Human | Stomach | SIM | 1.01e-24 | 6.14e-01 | 0.3139 |
| 284106 | CISD3 | EGC | Human | Stomach | GC | 2.54e-02 | 2.87e-01 | 0.1683 |
| 284106 | CISD3 | male-WTA | Human | Thyroid | PTC | 4.49e-16 | 9.31e-02 | 0.1037 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00516047 | Breast | Precancer | protein maturation | 28/1080 | 294/18723 | 6.45e-03 | 4.50e-02 | 28 |
| GO:005160413 | Breast | IDC | protein maturation | 35/1434 | 294/18723 | 6.18e-03 | 4.40e-02 | 35 |
| GO:005160422 | Breast | DCIS | protein maturation | 34/1390 | 294/18723 | 6.72e-03 | 4.66e-02 | 34 |
| GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
| GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
| GO:00516042 | Colorectum | MSS | protein maturation | 75/3467 | 294/18723 | 1.70e-03 | 1.53e-02 | 75 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:009742811 | Esophagus | ESCC | protein maturation by iron-sulfur cluster transfer | 14/8552 | 16/18723 | 6.78e-04 | 3.56e-03 | 14 |
| GO:00516046 | Liver | Cirrhotic | protein maturation | 121/4634 | 294/18723 | 3.54e-10 | 1.68e-08 | 121 |
| GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
| GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
| GO:0097428 | Oral cavity | OSCC | protein maturation by iron-sulfur cluster transfer | 11/7305 | 16/18723 | 1.56e-02 | 4.99e-02 | 11 |
| GO:005160416 | Oral cavity | LP | protein maturation | 122/4623 | 294/18723 | 1.37e-10 | 7.72e-09 | 122 |
| GO:00974281 | Oral cavity | LP | protein maturation by iron-sulfur cluster transfer | 9/4623 | 16/18723 | 6.82e-03 | 3.94e-02 | 9 |
| GO:00516049 | Prostate | BPH | protein maturation | 80/3107 | 294/18723 | 2.64e-06 | 4.23e-05 | 80 |
| GO:005160415 | Prostate | Tumor | protein maturation | 81/3246 | 294/18723 | 7.58e-06 | 1.13e-04 | 81 |
| GO:005160419 | Skin | cSCC | protein maturation | 117/4864 | 294/18723 | 1.27e-07 | 2.93e-06 | 117 |
| GO:00974283 | Skin | cSCC | protein maturation by iron-sulfur cluster transfer | 9/4864 | 16/18723 | 9.73e-03 | 4.31e-02 | 9 |
| GO:00516045 | Stomach | GC | protein maturation | 34/1159 | 294/18723 | 3.35e-04 | 5.33e-03 | 34 |
| GO:005160411 | Stomach | CAG with IM | protein maturation | 31/1050 | 294/18723 | 5.57e-04 | 8.22e-03 | 31 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CISD3 | SNV | Missense_Mutation | novel | c.80N>T | p.Trp27Leu | p.W27L | P0C7P0 | protein_coding | deleterious(0.04) | probably_damaging(0.986) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| CISD3 | SNV | Missense_Mutation | rs755126040 | c.128N>C | p.Leu43Pro | p.L43P | P0C7P0 | protein_coding | tolerated(0.29) | benign(0.291) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CISD3 | SNV | Missense_Mutation | novel | c.118N>C | p.Val40Leu | p.V40L | P0C7P0 | protein_coding | tolerated(0.09) | benign(0.042) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
| CISD3 | SNV | Missense_Mutation | novel | c.200N>C | p.Lys67Thr | p.K67T | P0C7P0 | protein_coding | tolerated(0.11) | possibly_damaging(0.883) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CISD3 | SNV | Missense_Mutation | novel | c.332N>T | p.Gly111Val | p.G111V | P0C7P0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CISD3 | insertion | Frame_Shift_Ins | novel | c.186_187dupTG | p.Gly63ValfsTer83 | p.G63Vfs*83 | P0C7P0 | protein_coding | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
| CISD3 | SNV | Missense_Mutation | novel | c.143A>C | p.Lys48Thr | p.K48T | P0C7P0 | protein_coding | deleterious(0) | possibly_damaging(0.598) | TCGA-RC-A7SB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |